OmicsFi’s Post

🌟 Revolutionizing Cancer Treatment with Personalized Precision Medicine! 🌟 The era of personalized precision medicine is flourishing, thanks to the widespread availability of Next-Generation Sequencing (NGS) data on solid tumors. This advancement enables the rapid identification of actionable genetic alterations, leading to highly targeted treatments. * With over 40% of biomarkers proving to be functionally relevant across multiple cancers, the future of cancer chemoprevention looks incredibly promising. Exciting times ahead for oncology and patient care! #PrecisionMedicine #CancerResearch #NGS #Oncology #TargetedTherapy #FutureOfMedicine [Dreikhausen L, Klupsch A, Wiest I, Xiao Q, Schulte N, Betge J, Boch T, Brochhausen C, Gaiser T, Hofheinz RD, Ebert M, Zhan T. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study. BMC Cancer. 2024 Apr 25;24(1):526. doi: 10.1186/s12885-024-12261-2. PMID: 38664720; PMCID: PMC11046933].

The 100,000 Genomes Cancer Programme recently made a significant advancement in the field of oncology by publishing integrated whole genome sequencing (WGS) data from 13,880 solid tumors. This analysis, encompassing a vast array of tumor types, was coupled with real-world insights into treatment and outcomes. The findings underscore the potential of WGS to detect a range of genetic alterations, including somatic small variants, copy number aberrations, and structural variants, which are crucial for guiding treatment decisions. This work revealed that >90% of brain tumors and >50% of colon and lung cancers exhibited genetic changes that could influence treatment strategies. Learn more about this cutting-edge research: https://hubs.ly/Q02xj6yg0 #CancerResearch #PrecisionMedicine #Genomics

https://lnkd.in/gWs8UBe3     Article title: Distinct genetic variants of early and late-onset prostate cancer   Author(S): Victor Chalfant#, Samuel Serrano#, Mohamed Al-Toubat*, Carlos Riveros#, Ahmed Elshafei and KC Balaji   Journal: Insights of Epigenetics and Chromatin Abstract: Background: The incidence of early-onset Prostate Cancer (PCa) has increased in the last two decades. Men diagnosed with PCa before age 55 have lower 5-year relative survival rates compared to patients diagnosed later in life. Given the enhanced lethality of early-onset PCa, our aim is to evaluate somatic differences between early and late-onset PCa. Methods: Patients with PCa were dichotomized into early (< 55 years old) and late-onset PCa (≥ 55 years old). Data is derived from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry. The GENIE registry contains sequenced tumor samples and clinical data across many cancers a total of 4,546 Patients and 5,740 samples were included with pathologically confirmed prostate adenocarcinoma. The data is derived from 17 cancer centers from 2011 to 2021. Patterns in somatic gene tumor profiles were compared between early-onset and late-onset PCa using a chi-square test and logistic regression. #Earlyonsetprostatecancer #Genesequencing #ERF #CDK12 #Genetherapeutics   #DNAMethylation #HistoneModifications #ChromatinRemodeling #EpigeneticRegulation #EpigeneticInheritance #ChromatinStructure #HistoneAcetylation #GeneExpression #EpigeneticModification #ChromatinArchitecture #ChromatinDynamics #EpigeneticMarkers #NonCodingRNAs #ChromatinOrganization #ChromatinFunction #DNAAccessibility #EpigeneticMemory #TranscriptionalRegulation #EpigeneticTherapy #ChromatinInteractions

🔬 Did you know that prostate cancer is the second most common type of cancer in men with 1 out of 9 men developing it at one point in their lives? 🔎 A recent genetic research have identified mutations which may help doctors determine who are more likely to have aggressive forms of prostate cancer enabling development of more individualized therapy for such patients. 🧬 Researchers at the Institute of Cancer Research in London have added to the number of inherited genetic mutations that can raise the chances of an aggressive kind of prostate cancer. This discovery reiterates the significance of genetic influences on the intensity of cancer. In genes like ATM, MLH1, MSH2, NBN, and BRCA2, locating specific mutations enables clinicians to predict disease progression more effectively, and as a consequence, to individualize therapeutic strategies. 🌱 This can potentially lead to better results for patients as well as improved quality-of-life measures by means of better healthcare provision. Let's celebrate this milestone in cancer research and the potential it brings for improved patient care. 🌟 #Prevealth #CancerResearch #Genetics #ProstateCancer #MenHealth #HealthcareInnovation Read more: https://lnkd.in/gZFUyaEG

🔍 Unveil the Secrets of Cancer Genetics with AviSeq™ BRCA Kit! 🔍 🌟 Discover the Power of Precision Medicine 🌟 🔬 AviSeq™ BRCA Kit – Your ultimate tool for analyzing genetic markers in breast, ovarian, and prostate cancer. Our state-of-the-art NGS library preparation kit targets the BRCA1, BRCA2, and TP53 genes, detecting critical germline and somatic mutations with unmatched accuracy. 💡 Why Choose AviSeq™ BRCA? Comprehensive Analysis: Targets key genes associated with cancer risk and DNA repair. Minimal Sample Requirements: Achieve precise results with just 10ng/ul of DNA from blood or tissue samples. Quick Turnaround: Prepare sequence-ready libraries in just ~6 hours. 🌍 Elevate Your Research: Join the forefront of cancer research and diagnostics with AviSeq™ BRCA Kit. Empower your work with the precision and reliability needed to make groundbreaking discoveries and improve patient outcomes. 📞 Learn More: Visit www.avcna.net 🔬 AviSeq™ – Transforming Cancer Genetics! 🌟 #AviSeq #BRCA #Genomics #CancerResearch #NGS #NextGenSequencing #PrecisionMedicine #Oncology #BreastCancer #OvarianCancer #ProstateCancer #GeneticTesting #Biotech #LifeSciences #ResearchInnovation #HealthcareInnovation

🔍 How can simply looking at cells through the Deepcell lens guide cancer therapy decisions? In collaboration with AbbVie (data presented at #AACR2024), we demonstrated direct linking between cell morphology to gene expression and function in a lung cancer patient tissue biopsy.   🔬 We identified a rare malignant subpopulation (Cluster 0) with a drastically different gene expression profile compared to the majority of the patient's cancer cells (Cluster 2). 💡 Through sorting, we uncovered key differences in gene expression and pathways, including upregulation of STAT3 (which promotes tumor growth, survival, angiogenesis, immune evasion, and inflammation) and NF-kB signaling (fueling inflammation, tumor survival, resistance to apoptosis, and metastasis) in this rare subpopulation. 🎯 These insights suggest therapeutically targeting STAT3 and NF-kB signaling to effectively combat Cluster 0. The results underscore #REM-I’s potential to unveil hidden cellular subtypes, drive groundbreaking cancer therapies, and transform patient outcomes. Start your journey to harness the power of AI for your application by requesting a demo here: https://lnkd.in/g_nPdRR4 Link to AACR poster here: https://lnkd.in/gF9zA-T4 #PrecisionOncology #CancerResearch #Deepcell #AACR2024 #CancerTherapies #Morpholomics

Understanding genetic factors in hereditary cancer helps tailor proactive management and preventive measures, aiming for the best possible patient outcomes and support. Some cancers have a stronger genetic predisposition, with hereditary syndromes making up around 3-20% of all cancer cases. Unilabs provides oncogenetic consultations which can unlock possible risk-reducing interventions and provide informed clinical decisions for the patient. Developments in next-generation sequencing allow us to quickly analyse multiple genes at once, helping identify harmful gene changes linked to hereditary cancers. Additionally, new treatments like PARP inhibitors and checkpoint inhibitors show promise for cancers with specific genetic mutations.  Learn more from Unilabs' Oncogenetics specialist Dr Zuzana Mazerikova.  https://lnkd.in/eN_vp_64 #Genetics #Oncology #Cancer #Healthcare 

Cancer genomics, a burgeoning field, delves into the genetic underpinnings of cancer. By scrutinizing the entire genome, researchers identify driver mutations pivotal in cancer initiation and progression. This molecular understanding enables precise molecular subtyping of cancers, guiding treatment decisions. Targeted therapies tailored to specific genetic alterations have emerged, enhancing treatment efficacy while minimizing side effects. Genomic profiling of tumors facilitates personalized medicine, optimizing therapeutic interventions. Furthermore, insights into resistance mechanisms and tumor heterogeneity gleaned from cancer genomics are invaluable for refining treatment strategies and predicting disease outcomes. In essence, cancer genomics is revolutionizing cancer care, offering hope for improved outcomes and better patient management.

The promising new technique offers a new avenue for both cancer detection and monitoring By:Mekhled Al-zaza Genetic changes in repetitive sequences are a hallmark of cancer and other diseases, but characterizing these has been challenging using standard sequencing approaches. Annapragada et al.(1) have developed ARTEMIS (Analysis of RepeaT EleMents in dISease) to call these repeat elements from whole-genome sequencing and created a machine learning model that is able to predict disease in patients with early-stage lung or liver cancer and have taken advantage of the new telomere-to-telomere reference genome to evaluate changes in repeat elements from liquid biopsies. This promising new technique offers a new avenue for both cancer detection and monitoring. References 1. Annapragada et al. Genome-wide repeat landscapes in cancer and cell-free DNA. SCIENCE TRANSLATIONAL MEDICINE 13 Mar 2024 Vol 16, Issue 738 DOI: 10.1126/scitranslmed.adj9283

Publication in #TheLancet about treating Cancer of #UnknownPrimary (#CUP). The #CUPISCO study reveals that genetic analysis of cancer cells with unknown origin can identify numerous targets for existing #TargetedTherapies developed for other cancer types. The large international study led by Heidelberg researchers, involving over 630 patients from 34 countries, found that about one-third of CUP patients could benefit from targeted treatments. These therapies significantly prolonged the time before disease progression compared to standard #Chemotherapy. Key findings: -> #GeneticTesting of tumor cells and blood samples identified actionable mutations in 1/3 of patients -> Targeted treatments extended progression-free survival by an average of 4 months -> #LiquidBiopsy proved as reliable as tissue samples for genetic analysis This research, led by Alwin Krämer, could revolutionise #CUPTreatment, potentially offering patients additional months to years of disease-free survival. The study also established new guidelines for CUP diagnosis and treatment, marking a significant step forward in #PrecisionMedicine for this challenging cancer type.   Congratulations to all the authors! The Phase 2-Study „CUPISCO" is registered under ClinicalTrials.gov (NCT03498521) and is financed by the company Hoffmann-La Roche More information in the press release: https://lnkd.in/edvvbiyw #CancerTreatment #diangnosis #Oncology #MedicalResearch #ClinicalTrial #patients #genetics DKFZ German Cancer Research Center   /bj